MolDX: Genomic Health™ Oncotype DX® Prostate Cancer Assay

Noridian Healthcare Solutions, LLC

**Please Note: This is a Proposed LCD.**
Proposed LCDs are works in progress and not necessarily a reflection of the current policies or practices. Proposed LCDs in an approval status display on the CMS MCD for public review.

**Contractor Information**

Contractor Name: Noridian Healthcare Solutions, LLC
Contract Number: 01112
Contract Type: A and B MAC

**Proposed LCD Information**

Source LCD ID: N/A
Proposed LCD ID: DL36364
Original ICD-9 LCD ID: N/A
Proposed LCD Version 3

Proposed LCD Title MolDX: Genomic Health™ Oncotype DX® Prostate Cancer Assay

CPT only copyright 2002-2014 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

AMA CPT The Code on Dental Procedures and Nomenclature (Code) is published in

ADA CDT Current Dental Terminology (CDT). Copyright (c) American Dental

AHA NUBC Association. All rights reserved. CDT and CDT-2010 are trademarks of the

Copyright Statements American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA. Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

Title XVIII of the Social Security Act (SSA), §1862(a)(1)(A), states that no Medicare payment shall be made for items or services that “are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.”

Title XVIII of the Social Security Act, §1833(e), prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.

42 Code of Federal Regulations (CFR) §410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

CMS National Coverage Policy CMS Internet Online Manual Pub. 100-02 (Medicare Benefit Policy Manual), Chapter 15, Section 80, “Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests”

CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) “Reporting ICD Diagnosis and Procedure
Coverage Indications, Limitations, and/or Medical Necessity

Noridian will provide limited coverage for the Oncotype DX® Prostate Cancer Assay (Genomic Health™) to help determine which patients with early stage, needle biopsy proven prostate cancer, can be conservatively managed rather than treated with definitive surgery or radiation therapy.

Background

In 2014, nearly 233,000 men in the US will be diagnosed with prostate cancer, which accounts for 14% of all new cancer diagnosis. More than 29,000 men will die from this disease representing 5% of all cancer deaths. Gratefully 98.9% of men are surviving at 5 years (SEER).

Coverage Indications, Limitations, and/or Medical Necessity

Many individuals do not need treatment for their prostate cancer in as much as their prognosis is excellent even without treatment. However, physicians and patients struggle to know who can safely be observed versus the subgroup that needs more aggressive treatment to achieve cure, and recognize that definitive treatment for localized prostate cancer can have lifelong morbidities (Resnick 2013).

Traditionally, clinicopathologic characteristics are utilized to determine risk and subsequent treatment. Several nomograms have been introduced to try to determine who is at risk of developing metastatic disease and who, if treated early, could avoid this outcome. A representative nomogram taken from the NCCN (and AUA), divides early prostate cancer into several groups based initially on life expectancy, with a second stratification using clinical exam, reassessment of life expectancy, biopsy (Gleason score), PSA and imaging after 5 years.

These groups are detailed below:

<table>
<thead>
<tr>
<th>Risk Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Low</td>
</tr>
<tr>
<td>Low</td>
</tr>
<tr>
<td>Intermediate</td>
</tr>
<tr>
<td>High</td>
</tr>
</tbody>
</table>
## Clinicopathologic Findings

- T1c AND
- Gleason score $\leq 6$ AND
- PSA $\leq 10$ ng/mL AND
- $< 3$ prostate cores with tumor AND
- $\leq 50\%$ tumor in any core AND
- PSA density of $< 0.15$ ng/mL/g

<table>
<thead>
<tr>
<th>Treatment Options</th>
<th>≥ 20 y life expectancy</th>
<th>≥ 10 y life expectancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Surveillance</td>
<td>RT or Brachy</td>
<td>RP (± LND)</td>
</tr>
<tr>
<td>RT or Brachy</td>
<td>RP (± LND)</td>
<td>RT or Brachy ± Adj Horm</td>
</tr>
<tr>
<td>RP (± LND)</td>
<td>RT or Brachy ± Adj Horm</td>
<td>RT + Adj Horm</td>
</tr>
</tbody>
</table>

- T2-T2a AND
- Gleason score $\leq 6$ AND
- PSA $\leq 10$ ng/mL

- T2b-T2c OR
- Gleason score $= 7$ OR
- PSA 10-20 ng/mL

- T3a OR
- Gleason Score 8-10 OR

- PSA $> 20$ ng/mL
Use of these stratification and treatment approaches has led to high cure rates for early stage prostate cancer, yet it is widely accepted that many men are over-treated to achieve this cure rate. In the PIVOT trial (Wilt 2012) men with early prostate cancer, initially randomized to radical prostatectomy or observation, showed that over 12 years there was no difference in absolute mortality between the groups. However, this study was hampered by several factors including:

- Only 731 of 5023 eligible patients chose to participate in the study based on randomization criteria.
- In the group randomized to RP: only 85% of the men received definitively therapy (79% surgery; 6% other).
- In the observational group: 10% of the observation group received RP initially and additional 20% eventual received definitive treatment.
- Despite broad inclusion criteria, >50% of patients had a PSA of <10 (median PSA of 7) and had biopsy proven T1c disease. Although there were a significant number of patients with Gleason score >= 7 (25%), 40% of men were classified initially as being low risk; and 30% were intermediate.

Although subgroups were small, it appears that high-risk groups (including those with PSA > 10) benefitted from RP. Furthermore, there was a trend for the intermediate risk patients to benefit from RP as well. The small number of participants to eligible study patients, and the high rate of crossover (both initially and subsequently) demonstrate the difficulty of doing observation trials in the United States.

Although there is early data that may suggest that some patients with intermediate
risk prostate cancer could potentially be considered for active surveillance (AS) (Gleason Score 3+4 = 7, PSA < 10), the NCCN and other mainstream groups still do not recommend this approach, with the NCCN stating, “Active surveillance of intermediate and high-risk clinically localized cancers is not recommended in patients with life expectancy > 10 years as a category 1 recommendation.

**Oncotype DX® Prostate Cancer Assay Prostate Cancer Assay**

**Test Description**

Oncotype DX® Prostate Cancer Assay is prostate biopsy-based 17-gene RT-PCR assay, representing four molecular pathways (androgen signaling, cellular organization, stromal response and proliferation), that provides a biologic measure of cancer aggressiveness. The assay is indicated for men who are considered candidates for active surveillance (AS) (those with NCCN® very low- and low-risk prostate cancer). The assay is designed to inform decisions between AS and immediate treatment.

**Test Performance**

The clinical performance of this assay was assessed in several validation studies. The first was a prospective-retrospective study conducted in a contemporary fit-for-purpose cohort of 395 prostate cancer patient with NCCN very low-, low- and intermediate-risk disease who were considered candidates for AS but who had opted to have radical prostatectomy at a university center from 1997-2011. The objectives were to validate the Genomic Prostate Score (GPS) as a predictor of adverse pathology (AP) at radical prostatectomy, a hallmark of aggressive disease, and to determine whether the GPS added independent predictive information beyond standard clinical and pathologic data. The assay was successfully performed in 96% of needle biopsy specimens. Ninety-nine point five percent (99.5%) of samples with =10 ng/m; RNA yielded a GPS result. Per the pre-specified primary analysis, the GPS was a significant predictor of AP (p=0.002). While conventional clinical risk assessment tools stratified risk, the incorporation of the GPS identified the wide range of biologic risk within each conventional (NCCN and CAPRA) risk group. In multivariable analysis, the GPS was found to predict AP at radical prostatectomy (RP), even after accounting for several standard clinical risk factors (biopsy GS, clinical T-stage, baseline PSA and age). Further analyses showed that by incorporating the GPS results with previously defined clinical risk assessment tools (NCCN, CAPRA), more patient were identified with very low- and low-risk biologic potential and as appropriate candidates for AS. Together, the GPS and the NCCN risk group provide a more accurate prediction of AP.

For the second clinical validation study, a large cohort with a high proportion of African-American men (20%) in the Center for Prostate Disease Research (CPDR) multi-center longitudinal study was identified to test the association of GPS with tumor aggressiveness. Three endpoints for tumor aggressiveness were measured: AP
at surgery (actionable); biochemical recurrence (BCR), longer-term; and metastasis (longer-term). This prospective-retrospective study included 402 men with NCCN very low-, low- and intermediate-risk prostate cancer treated with RP at two US military medical centers between 2007-2011. In pre-planned, univariate analyses, GPS was validated as a significant predictor of BCR (primary objective) and confirmed as a significant predictor of AP (first secondary objective) after adjustment for biopsy GS. In addition, while there were very few metastatic events in this low- to intermediate-risk population (n=5 events), there was a strong association of GPS with metastatic recurrence. In multivariable analyses, GPS continued to be strongly associated with BCR and AP after adjustment for NCCN risk group, indicating that GPS adds value beyond standard clinico-pathologic features. A broad and overlapping range of GPS values was observed within each NCCN risk group, age quartile, and racial group. Importantly, GPS distribution, median values, and association of GPS with aggressive prostate cancer outcomes were similar between African-American and Caucasian men.

The incorporation of GPS into risk assessment for AP improved the AUC from 0.63 (NCCN alone) to 0.72 (GPS and NCCN) within the subset with biopsy GS 3+3 and low-volume 3+4 disease, and the AUC for NCCN alone was 0.60 compared with 0.69 by adding GPS (p=0.001). For BCR, the risk profile curve demonstrates a wide range of five-year risk of BCR as GPS increases. The incorporation of GPS improved the c-statistic for NCCN from 0.59 (NCCN alone) to 0.68. The AUC with the use of NCCN risk stratification alone ranges between 0.09 and 0.13. The additional improvement in AUC when GPS is used together with NCCN is 0.09 in all of the above comparisons. Thus, when GPS is combined with NCCN, the AUC, or c-statistics, are improved by a comparable amount to the improvement observed with NCCN alone.

The potential usefulness of this test is that it allows physicians to determine which patients with early prostate cancer are candidates for active surveillance and are more likely to have a good outcome without needing to receive definitive treatment.

Criteria for Coverage

The Oncotype DX® Prostate Cancer Assay is covered only when the following clinical conditions are met:

- Needle biopsy with localized adenocarcinoma of prostate (no clinical evidence of metastasis or lymph node involvement), and
- Patient stage as defined by the one of the following:
  - Very Low Risk Disease (T1c AND Gleason Score = 6 AND PSA = 10 ng/mL AND <3 prostate cores with tumor AND = 50% cancer in any core AND PSA density of < 0.15 ng/mL/g) OR
  - Low Risk Disease (T1-T2a AND Gleason Score = 6 AND PSA = 10 ng/mL), Patient has an estimated life expectancy of greater than or equal to 10 years, and
Patient has a life expectancy of 10-20 years,
Patient is a candidate for and is considering conservative therapy and yet and
would be eligible for definitive therapy (radical prostatectomy, radiation
therapy or brachytherapy), and
Patient has not received pelvic radiation or androgen deprivation therapy
prior to the biopsy, and
Test is ordered by a physician certified in the Genomic Health™ Oncotype
DX® Prostate Cancer Assay Certification and Training Registry (CTR), and
Patient is monitored for disease progression according to active surveillance
guidelines as recorded in NCCN guidelines, and
Physician must report the development of metastasis or prostate cancer
deaths in patients not treated definitively who were deemed low risk by the
assay.

Certification and Training Registry (CTR) Program

Because of the complicated nature of management decisions utilizing the Oncotype
DX® Prostate Cancer Assay and the potential for adverse harm to patients if the test
is not used appropriately, testing must be furnished only by physicians who are
enrolled in a MolDX approved Genomic Health™ Oncotype DX® Prostate Cancer
Assay CTR program. This serves to assure the appropriate selection of patients,
compliance with management decisions and stringent follow up to ensure the
benefits of the test outweigh its risks. As part of this requirement Genomic Health™
will provide to the CMS MolDX contractor (currently Palmetto GBA) reports every
6 months in a mutually agreed upon format.

The goals of the Genomic Health™ Oncotype DX® Prostate Cancer Assay CTR
program are as follows:

- To ensure that physicians understand the limitation of the test based on its
  validation,
- To inform prescribers and patients on the safe-use conditions for Oncotype
  DX® Prostate Cancer Assay™,
- Make a good faith effort to identify any safety concerns from the use of the
  test,
- Facilitate understanding of the incremental clinical utility of the test versus
  adherence to current NCCN guidelines.

Noridian expects Genomic Health™ to:

- Establish and maintain the Oncotype DX® Prostate Cancer Assay
  Certification and Training Registry (CTR);
- Ensure that healthcare providers who order the Oncotype DX® Prostate
  Cancer Assay score are registered and certified in the Oncotype DX®
Prostate Cancer Assay CTR program and that the Oncotype DX Prostate Cancer Assay is available only through these providers;

- Maintain a secure registry database of Genomic Health™ Oncotype DX® Prostate Cancer Assay CTR providers and obtain from referring physicians;
  - NCCN risk group and treatment recommendation based on current NCCN guidelines prior to receipt of test result;
  - Test result (i.e., GPS + NCCN risk group), and
    - Treatment recommendation based on test results, and
    - Physician-patient treatment decision, and
    - Report utilization data by clinico-pathologic staging;
    - Any subsequent change in patient or physician treatment decision, even if the patient has not progressed, and
    - Immediately report (for patients not treated definitively who were deemed very low or low risk by the assay:
      - Progression as defined by current NCCN guidelines for patients on AS, or
      - Development of metastases, or
      - Prostate cancer deaths.

- Share all required data and reports in a HIPAA complaint fashion.

Proposed Process Information

**Documentation Requirements**
The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See “Coverage Indications, Limitations, and/or Medical Necessity”) This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures.

Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and shall be made available upon request to Noridian or other Medicare entity.

**Associated Information**
References
5. NCCN Prostate Cancer Guideline 2014.2

<table>
<thead>
<tr>
<th>Meeting Date</th>
<th>Meeting Information</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/2015</td>
<td>The open public meeting will be held at the following location: Embassy Suites Flamingo Ballroom 4315 Swenson St. Las Vegas, NV 89119</td>
<td>American Samoa, California - Entire State, Guam, Hawaii, Nevada, Northern Mariana Islands, California - Northern, California - Southern</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Meeting Date</th>
<th>Meeting Information</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/09/2015</td>
<td>The Pacific Club Card Room 1451 Queen Emma St Honolulu, HI 96813</td>
<td>American Samoa, Guam, Hawaii, Northern Mariana Islands</td>
</tr>
<tr>
<td>10/21/2015</td>
<td>DoubleTree by Hilton San Francisco Airport Tiburon/Sausalito Room 835 Airport Boulevard Burlingame, CA 94010</td>
<td>California - Entire State, California - Northern, California - Southern</td>
</tr>
</tbody>
</table>
Comment Period Start Date: 10/01/2015
Comment Period End Date: 12/07/2015
Released to Final LCD Date: Not yet released.
Reason for Proposed LCD: Creation of Uniform LCDs... Creation of Uniform LCDs With Other MAC Jurisdiction

Proposed LCD Contact:
Noridian Healthcare Solutions, LLC JE Part B Contractor Medical Director(s)
Attention: Draft LCD Comments
PO Box 6783
Fargo, North Dakota 58108-6783
policyb.drafts@noridian.com

Coding Information

Bill Type Codes
Revenue Codes

CPT/HCPCS Codes

Does the CPT 30% Coding Rule Apply? No

ICD-10 Codes that Support Medical Necessity

Note: Performance is optimized by using code ranges.

ICD-10 Codes that DO NOT Support Medical Necessity

Note: Performance is optimized by using code ranges.
Additional ICD-10 Information

Associated Documents

Attachments
There are no attachments for this LCD.

Related Local Coverage Documents
This LCD version has no Related Local Coverage Documents.

Related National Coverage Documents
This LCD version has no Related National Coverage Documents.

All Versions
Version 3 - Updated on 08/12/2015 17:02:56, by Christine.Burnside@noridian.com, with effective dates N/A - N/A (Approved).

Version 2 - Updated on 08/10/2015 13:11:14, by Cheryl.Ryan@noridian.com, with effective dates N/A - N/A.

Version 1 - Updated on 08/10/2015 12:59:17, by Cheryl.Ryan@noridian.com, with effective dates N/A - N/A.